

# Deliverable

D6.1 - Plan for Dissemination, Communication and Exploitation of Results – Second version (M18)

WP:	6
Document Type:	R
Version:	2
Project Information:	Towards a sustainable pharmaceutical production
Grant Agreement n°:	101057816
Project Dates:	June 1st 2022 – May 31st 2026

Horizon Europe Grant Agreement N° 101057816 TRANSPHARM





#### **DOCUMENT INFORMATION**

Project Name	TransPharm	
Deliverable Title/Number	D6.1	
Description         Plan for Dissemination, Communication and Exploitation of Results		
Lead beneficiary	Ecologic Institut gemeinnützige GmbH	
Lead Authors Rodrigo Vidaurre		
Contributors	Marie Gaillard, Chiara Mazzetti	
Contractual delivery date:	30/11/22 (M6)	
Actual delivery date: 14/12/22 (M7) – Updated 14/02/24 (M21)		
Sensitivity	PU - Public	

#### **DOCUMENT APPROVAL**

NAME	ORGANISATION	ROLE	ACTION	DATE
Rodrigo Vidaurre	Ecologic	WP leader	Approved	14/02/2024
Guadalupe Vinado	Benkei	РМО	Approved	14/02/2024
Christian Stevens	UGent	Coordinator	Approved	14/02/2024

#### **DOCUMENT HISTORY**

VERSION	DATE	MODIFICATIONS	AUTHORS
V1	28/11/22	First draft	Rodrigo Vidaurre
V2	14/12/22	Update after review partners	Rodrigo Vidaurre
V3	24/01/24	Update	Rodrigo Vidaurre
V4	14/02/24	Update after review partners	Guadalupe Vinado
VF	14/02/24	Coordinator approval	Christian Stevens

*To request a change to this document, contact the Document Author.* 

#### **CONFIGURATION MANAGEMENT**

NATURE OF DELIVERABLE		
R	Document, report (excluding the periodic and final reports)	
DEC	Websites, patents filing, press & media actions, videos, etc.	Х
DEM	Demonstrator, pilot, prototype, plan designs	
OTHER	Software, technical diagram, algorithms, models, etc.	





ETHICS	Deliverables related to ethics issues.	
DATA	Data sets, microdata, etc	
DMP	Data Management Plan	
SCURITY	Deliverables related to security issues	

DISSEMINATION LEVEL		
PU	Public, fully open, e.g., web (Deliverables flagged as public will be automatically published in CORDIS projects.)	Х
SEN	Sensitive, limited under the conditions of the Grant Agreement	
Classified EU-R	EU RESTRICTED under the Commission Decision No2015/444	
Classified EU-C	CONFIDENTIAL under the Commission Decision No2015/444	
Classified EU-S	EU SECRET under the Commission Decision No2015/444	

ACRONYM/ABBREVIATIONS	
API	Active Pharmaceutical Ingredient
CA	Consortium Agreement (contractual document between members of the consortium)
DoA	Description of Action (technical annex to the Grant Agreement)
EC	European Commission
EU	European Union
FTP	Funding and Tenders Portal: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home
GA	Grant Agreement (contractual document between EC and beneficiaries)
IPR	Intellectual Property Rights
ко	Kick Off (meeting)
МС	Management Coordinator
МТА	Milestones Trend Analysis
PC	Project Coordinator
РМО	Project Management Office
TL	Task Leaders
WP	Work Package
WPL	Work Package Leaders



### Acknowledgements

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement N° 101057816. The authors would like to thank European Commission for the funding.

The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Reproduction is authorised provided the source is acknowledged.

#### Disclaimer

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.





### CONTENTS

1	Executive summary	6
2	Description of the deliverable objective and content	7
3	Communication and dissemination actions: overview, timeplan, responsibilities	9
4	Exploitation of project results: actions' overview, timeplan, responsibilities	15

### LIST OF TABLES

Table 1: Overview of WP6's tasks and their objectives.	7
Table 2: Overview of finalised TransPharm communication and dissemination actions / St	atus at
M18	9
Table 3: Overview of upcoming TransPharm communication and dissemination actions / 9	Status
at M18	10
Table 4: Overview of project Key Exploitable Results, involved partners and KER type.	15
Table 5: Overview of exploitation-activity related plans / Status M18	16

### **TABLE OF FIGURES**

Figure 3-1: Mindmap cutout with an overview of the three training modules for academia /	
industry and showing responsibilities for Module 1 – Chapter 1	12
Figure 3-2: Gantt chart overview of the training materials development	13



### **1 EXECUTIVE SUMMARY**

The research project "TransPharm - Towards a sustainable pharmaceutical production" is a fouryear Research and Innovation Action (RIA) which has been accepted for funding with the European Union's Horizon Europe Framework Programme (HE/2021-2027), under Grant Agreement n°101057816.

This document presents the second version of the project's Plan for Communication, Dissemination and Exploitation of Results, first developed in Month 6 of the project and to be updated in Months 18, 30 and 42. This report represents the first update and has been finalised in Month 20.





## 2 DESCRIPTION OF THE DELIVERABLE OBJECTIVE AND CONTENT

The research project *"TransPharm - Towards a sustainable pharmaceutical production"* is a four-year Research and Innovation Action (RIA) which has been accepted for funding with the European Union's Horizon Europe Framework Programme (HE/2021-2027), under Grant Agreement n°101057816. This document presents the second, updated version of the project's **Plan for Communication, Dissemination and Exploitation of Results**. The first version was developed in Month 6 of the project; this version corresponds to the update due in Month 18. There will be further updates in Months 30 and 42.

Work Package 6's name – *"Stakeholder engagement, communication, dissemination, exploitation and training activities"* – provides already a summary of the work package's different areas of action. Table 1 presents an overview of the WP's tasks and their main objectives.

Tasks	Main objective
Task 6.1: Plan for Stakeholder Engagement, Dissemination and Exploitation of Results	Development and update of planning for tasks 6.3 - 6.6.
Task 6.2: Data Management Plan	Development and update of project's Data Management Plan.
Task 6.3: Stakeholder engagement	Engaging with stakeholders (researchers, regulators, industry) to provide relevant inputs to WPs 2, 3 and 5 to increase relevance of task's outputs.
Task 6.4: Communication and dissemination	Sharing project news and outcomes with target groups.
Task 6.5: Exploitation management of project results	Facilitating exploitation of project results.
Task 6.6: Training activities	Developing training materials targeting industry / academia, healthcare actors, and potentially the broader public and water managers

Table 1: Overview of WP6's tasks and their objectives.

This report (D6.1) presents the updated outcomes and planning for Tasks 6.4 to 6.6. (A separate deliverable (D6.8) presents the planning for Task 6.3.) Chapter 3 presents an overview of the project's communication and dissemination actions performed within *Task 6.4: Communication and dissemination* and *Task 6.6: Training activities*. Chapter 4 provides an overview of the actions related to the exploitation of project results carried out within *Task 6.5: Exploitation management of project results*.



#### TransPharm's **main goals** are:

- Help move towards a more sustainable European pharmaceutical production of Active Pharmaceutical Ingredients (APIs)
- To develop more sustainable and greener APIs that simultaneously reduce the environmental footprint and the dependence on third countries for API production.
- Deliver digital tools and guidelines, also based on artificial intelligence, for the development of greener pharmaceutical products and APIs, as well as models to judge their impact.
- Elaborate business cases for sustainable pharmaceutical products or APIs and what is needed to bring them to the market.
- Transfer key project results and knowledge towards targeted stakeholders.

TransPharm aims to achieve the following **breakthroughs**:

- The project will propose a multi-level approach to provide researchers and regulators with a **better understanding of the environmental impact of pharmaceuticals**. Tools and guidelines will be developed and shared together with the project key results with targeted stakeholders such as researchers and regulators. Besides them, the wider community will be targeted to foster the understanding of the environmental impact of pharmaceuticals.
- The project's objective is to generate scientific evidence related to the development, production, use and disposal of pharmaceuticals, so that public authorities can inform pharmaceutical strategies and policies based on scientific evidence.
- The project will contribute to the development and future use of greener pharmaceuticals by
  - i. Creating a centre of excellence, with training actions dedicated to the young generation and researchers,
  - ii. Provide scientific evidence that might help to the development of new standards,
  - iii. Providing scientific evidence so that public authorities can inform pharmaceutical strategies and polices,
  - iv. Empowering the healthcare sector and general public to a more sustainable use of pharmaceuticals, including sustainable procurement of pharmaceuticals.

It will assure **reliable access to key manufacturing capacity and will support bringing back production to Europe**. The EU will create an autonomous leadership position with on demand, faster, cheaper and more sustainable manufacturing of medicines products.





# 3 COMMUNICATION AND DISSEMINATION ACTIONS: OVERVIEW, TIMEPLAN, RESPONSIBILITIES

With the aim of facilitating uptake of project results, TransPharm outcomes will be communicated to a variety of relevant stakeholders (incl. industry, academia, and policy makers) via targeted communication actions. The wide-ranging actions span from conducting training events and producing training materials to organising conference events and publishing a white paper for policy makers.

Table 2 below provides an overview of already finalised actions related to communication and dissemination, whereas Table 3 provides an overview of upcoming actions.

Table 2: Overview of finalised TransPharm communication and dissemination actions / Status at M18

ACTIONS	PARTNER RESPONSIBLE
Set-up of communications tools internal to project (Sharepoint, email distribution lists)	UGent
Development of a Visual Identity for the project	Ecologic
Development of templates for project outputs (Powerpoint template, Word template (basic and deliverable), poster templates (landscape and portrait), Newsletter template)	Ecologic
Establishment of social media communication accounts (Twitter, LinkedIn, Instagram)	UGent
Set-up of a project website	UGent
Official PowerPoint presentation of the TransPharm project	UGent
2 press releases (including project's Newsletter #1)	UGent / Benkei
Establishing Scientific Advisory Board	UGent / Benkei
1 <sup>st</sup> project workshop	RIVM / RU / LEUPHANA / Ecologic
6 poster presentations	Various
9 oral contributions	Various
1 published manuscript	UGent





Table 3: Overview of upcoming TransPharm communication and dissemination actions / Status at M18

ACTIONS		SPECIFICATIONS	PARTNER RESPONSIBLE	DUE DATE		
Elaboration of a white summarising scientific development of green pharmaceuticals	evidence for the	Project's outputs, guidelines, rules and tools	UGent	M44 (beta version in M38)		
Yearly training events / workshops	Open demonstration 1		LEU	M24 (tbc)		
w/ healthcare value chain and healthcare sector actors (2	Open demonstration 2		tbc	M36 (tbc)		
physical events + 2 webinars)	Final Symposium	15 industrial partners	Orion	M48		
Training blocks focuse stakeholder groups (in	•	Sustainable choices for pharmaceuticals (w/ themes from WP2,3&4)	<b>UoY</b> (w/ support from ECO, LEU, UGent, RIVM)	M48		
regulators, academia,	•	Water management	<b>UoY</b> (w/ support from RU, ECO, RIVM)			
One video of awarenes part of general public		Highlight the environmental impact of pharmaceuticals	RIVM + ECO	M46		
Project newsletters (in summary / year)	cl. short public	Once-yearly newsletters	UGent	M24; M36; M48		
Open science publicati	ons	15 publications or more	ns or more All			
2 specific communicati	ons	Format of communications to be defined. Options include journal or magazine articles, holding presentations at meetings convened by EWRA / EUREAU, etc.	RU, RIVM, ECO	By M48		
10 presentations at rel international conferen and/or fairs		Projects results presented in conference participation	All	Ву М48		





Over the last eight months WP6 work has focused strongly on the development of training materials for academia / industry. The following figures provide an overview of the planning approach involving all project partners in the development of training materials, with a mindmap cutout showing the responsibilities for Module 1 – Chapter 1, and a Gantt chart overview of the process. The development of this part of the training materials is expected to be finalised by August 2024.








Figure 3-1: Mindmap cutout with an overview of the three training modules for academia / industry and showing responsibilities for Module 1 – Chapter 1.





			Decem	ber 2023	Januar	y 2024	Feb	ruary 2024	1	March 2024		April 2024	May 20	024	June 2024		July 2024		Au
sk	Start date	Due date	WN	49 WN50 WN51	WN52 WN1	WN2 WN3 WN4	14 WNV5	WN6 WN7 V	NN8 NN9	WN10 WN1	1 WN12 WN1	13 WN14 WN15 WN16 WN17	WN18 N	WN19 WN20 WN21 WN	122 WN23 WN24	WN25 WN26	WN27 WN	128 WN29 WN30	WN31
P6.6 - Training activities	04.12.2023	02.08.2024	-									<b>^</b>							—
Training materials academia / industry - UoY author	04.12.2023	31.05.2024							_	<b>^</b>					<ul> <li>Training materi</li> </ul>	ials academia / i	industry - Uo	oY author	
— Agreement module structure with partners at GAM	04.12.2023	08.12.2023		Agreement mod	ule structure wi	th partners at GAM													
OPTION: Additional meeting with editorial board to finalise mo	25.12.2023	29.12.2023				I: Additional meeting	g with editor	rial board to finali	ise module :	tructure									
Email to partners with responsibilities, timeplan, example articl	18.12.2023	22.12.2023			Email to partner	s with responsibilitie	ies, timeplar	n, example article	e, doodle for	meeting.									
Email to editorial board with responsibilities, timeplan, exampl	08.01.2024	12.01.2024				Email to ed to	torial board	with responsibilit	ties, timepla	n, example arti	cle, doodle for	meeting.							
Agreement responsibilities drafting, reviewing and multimedia	04.12.2023	19.01.2024				Agree	ement resp	onsibilities drafti	ng, reviewin	g and multimed	ia contributions	S							
···· UoY: finalise 1st drafts	04.12.2023	09.02.2024						UoY: final	ise 1st draft	s									
UoY: 1st draft to review partners	12.02.2024	12.02.2024							st draft to re	view partners									
- 1st review meeting (one per partner). From partners: additiona	19.02.2024	27.02.2024							1	t review meetir	ig (one per par	tner). From partners: additional to	opics, gene	eral input, data sources, o	concepts for multir	nedia contributio	ons.		
···· UoY: finalise 2nd drafts	28.02.2024	22.03.2024									UoY:	finalise 2nd drafts							
UoY: 2nd draft to review partners	25.03.2024	25.03.2024										Y: 2nd draft to review partners							
	01.04.2024	09.04.2024											a (one per	partner): Partners provid	e feedback on 2nd	draft			
- 2nd review meeting (one per partner) (same meeting): UoY pr	01.04.2024	09.04.2024												partner) (same meeting):			edia contrib	utions	_
- Partners finalise concept for multimedia contributions, send to	10.04.2024	26.04.2024												nalise concept for multim				Sucho	_
··· UoY: Email feedback re, concept for multimedia contributions	29.04.2024	03.05.2024												Y: Email feedback re. co			•••••••		_
Partners record multimedia contributions, send to UoY	06.05.2024	24.05.2024								-					ners record multim		es condito l	le¥	_
UoY: finalise 3rd drafts	10.04.2024	26.04.2024											HeV: finali	se 3rd drafts	ners record maran	eura contribution	is, send to t	501	
	29.04.2024	03.05.2024								-				view meeting UoY, LEU,					_
																ty partners, RIVI	M		
UoY: Update of drafts	06.05.2024	24.05.2024											PL		Update of drafts				
<ul> <li>UoY: upload completed articles to platform.</li> </ul>	27.05.2024	31.05.2024													UoY: upload co				
Training materials academia / industry - partner authors (modul		07.06.2024							_			·····				g materials acad	demia / indus	stry - partner author	s (m
···· Partners: draft development	22.01.2024	23.02.2024								rs: draft develo									
···· Authors: 1st drafts to reviewers/UoY	26.02.2024	26.02.2024							- Au	hors: 1st drafts									
Joint review meeting author partners / reviewers / multimedia	04.03.2024	15.03.2024									Joint review	meeting author partners / reviewe	ers / multin	nedia contributors. From	reviewers addition	al topics, genera	al input, dat	a sources. From mi	ultim
···· Authors: 2nd draft delopment	18.03.2024	29.03.2024									▶	Authors: 2nd draft delopment							
···· Authors: 2nd drafts to reviewers/UoY	01.04.2024	01.04.2024										Authors: 2nd drafts to review							
2nd (final) joint review meeting: Reviewers provide final feedb	08.04.2024	19.04.2024										2nd (final	ial) joint re	view meeting: Reviewers	provide final feed	back on 2nd dra	ft, authors/re	eviewers provide fe	edba
2nd (final) joint review meeting (same meeting): authors/revie	08.04.2024	19.04.2024										2nd (final	al) joint re	view meeting (same mee	ting): authors/revie	ewers provide fe	edback on c	concepts for multime	adia
Partners finalise concept for multimedia contributions, send to	22.04.2024	03.05.2024											Pa	rtners finalise concept fo	r multimedia contr	ibutions, send to	UoY		
UoY: Email feedback re. concept for multimedia contributions	06.05.2024	10.05.2024												UoY: Email feedbac	k re. concept for m	nultimedia contri	butions		
····, send to UoY	13.05.2024	31.05.2024													, send to UoY				
···· Authors: 3rd drafts	06.05.2024	17.05.2024												Authors: 3rd	l drafts				
···· Review meeting UoY, LEU, Ecologic, university partners, RIVM	20.05.2024	24.05.2024											-	Revi	iew meeting UoY, I	EU, Ecologic, u	niversity pa	rtners, RIVM	
Authors: Update of drafts	27.05.2024	31.05.2024													Authors: Updat				
- UoY: upload completed articles to platform.	03.06.2024	07.06.2024													UoY: up		articles to p	latform.	
Final steps	10.06.2024	02.08.2024																	
- UoY: Development of guizzes	10.06.2024	28.06.2024													- i		UoY: Develo	pment of guizzes	
··· UoY: Quizzes sent to authors for check	01.07.2024	01.07.2024																zzes sent to author	s for
- Authors: Email feedback on guizzes	08.07.2024	12.07.2024																Authors: Email fe	
- UoY: Update of guizzes	15.07.2024	26.07.2024																	JoY:
UoY: Upload completed guizzes to platform	29.07.2024	29.07.2024																	
· · · · · · · · · · · · · · · · · · ·																			1 19
I Ensuring accessibility of videos (subtitles, transcripts)	17.06.2024	02.08.2024														L			_

Figure 3-2: Gantt chart overview of the training materials development





In addition to the project's own communication and dissemination actions, TransPharm has initiated communication with sister projects funded under the same Horizon Europe call to develop synergies and joint communication activities. It is for instance foreseen that sister project representatives participate in the yearly training events / workshops.





# 4 EXPLOITATION OF PROJECT RESULTS: ACTIONS' OVERVIEW, TIMEPLAN, RESPONSIBILITIES

**Exploitation** is the utilisation of results in further research activities other than those covered by the action concerned, or in developing, creating and marketing a product or process, or in creating and providing a service or standardisation of activities.

In addition to the four Key Exploitable Results (KERs) identified in the first version of this report, two additional ones were identified over the last 12 months, bringing them up to a total of six KERs. Three of these KERs are currently classified as leading to commercially exploitable results, whereas the three remaining are currently seen as public. The following table provides an overview of the KERs, the partners involved and their type.

Key Exploitable Result (KER)	Partners involved in KER development	Type of KER (commercial / public)				
Software toolkit for multistep chemistry	UGENT	Licensing (commercial) or Open Source + OA data (public)				
Assessment tools for sustainability, ecotoxicity, environmental degradation and human safety	RU, UH, RIVM	Public + OA data				
Prediction tools for sustainability, ecotoxicity, environmental degradation and human safety	RU, UH, UGENT	Public + OA data				
New molecules	UGENT, LEU, CIRCA	Patents (commercial)				
New production routes for API	UGENT, LEU, CIRCA, UH, KELADA, ORION, LIOS	Patents and industrial know-how (commercial)				
Training platform	UoY, ECOLOGIC, LEU	Public				

Table 4: Overview of project Key Exploitable Results, involved partners and KER type.

The exploitation activities will be based on these 6 KERs and will enable the development of the different plans listed below.





ACTIONS	SPECIFICATIONS	PARTNER RESPONSIBLE	DUE DATE		
Exploitation Roadmap and Business Plans	This will provide guidance on the exploitation of the products and services through networking analysis, analysis of business models, routes for exploitation, the target user groups and markets and competitor analysis. This will facilitate appropriate management of the knowledge generated in the project and protection of the intellectual property generated. The plan will identify the potential of the TransPharm deliverables, the demand and target groups by investigating:	Benkei	M48		
Products/service potential	Identification of products or services that have potential for commercial exploitation.	Benkei	M48		
Market Potential	Identification of potential users (target groups) of products or services. This will be carried out by engaging with stakeholders to ascertain their needs and interests.	Benkei	M48		

#### Table 5: Overview of exploitation-activity related plans / Status M18

This set of actions will be reviewed at regular intervals by WP representatives as well as by members of the Scientific Advisory Board, who have been identified as being knowledgeable in the relevant technical areas. This will inform Task 6.5 (M12-48) led by Benkei with input from all partners.